Magnesium Depletion in Patients Receiving Cisplatin-based Chemotherapy

Clinical Oncology

Volumn 18, Issue 9, 2006, Pages 710-718

  Hodgkinson, E ^a   Neville Webbe, H L ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; cisplatin; hypomagnesaemia; magnesium; supplementation

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; MAGNESIUM; METHOTREXATE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; FREQUENCY ANALYSIS; HUMAN; HYPOMAGNESEMIA; INCIDENCE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; MIDDLE AGED; NEOPLASMS;

EID: 33749063400     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.06.011     Document Type: Article

References (45)

1. Schilsky R.L., and Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90 (1979) 929-931
2. Vogelzang N.J., Torkelson J.L., and Kennedy B.J. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56 (1985) 2765-2770
3. Bellin S.L., and Selim M. Cisplatin-induced hypomagnesemia with seizures: a case report and review of the literature. Gynecol Oncol 30 (1988) 104-113
4. Schilsky R.L., Barlock A., and Ozols R.F. Persistent hypomagnesaemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 66 (1982) 1767-1769
5. Blachley J.D., and Hill J.B. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95 (1981) 628-632
6. Daugaard G., and Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25 (1989) 1-9
7. Capizzi R.L. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 26 2 suppl 7 (1999) 72-81
8. Bitran J.D., Desser R.K., Billings A.A., et al. Acute nephrotoxicity following cis-dichlorodiammine-platinum. Cancer 49 (1982) 1784-1788
9. Bell D.R., Woods R.L., and Levi J.A. Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting. Eur J Cancer Clin Oncol 21 (1985) 287-290
10. Lam M., and Adelstein D.J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8 (1986) 164-169
11. Agus Z.S., Wasserstein A., and Goldfarb S. Disorders of calcium and magnesium homeostasis. Am J Med 72 (1982) 473-488
12. Lager H., and Daugaard G. Cisplatin and hypomagnesaemia. Cancer Treat Rev 25 (1999) 47-58
13. Stewart A.F., Keating T., and Schwartz P.E. Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol 153 (1985) 660-665
14. Hayes F.A., Green A.A., Senzer N., et al. Tetany: a complication of cis-dichlorodiammineplatinum (II) therapy. Cancer Treat Rep 63 (1979) 547-548
15. Vokes E.E., Mick R., Vogelzang N.J., et al. A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer 62 (1990) 1015-1017
16. Loehrer P.J., and Einhorn L.H. Cisplatin. Ann Intern Med 100 (1984) 704-713
17. Buckley J.E., Clark V.L., Meyer T.J., et al. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 144 (1984) 2347-2348
18. Weisinger J.R., and Bellorin-Font E. Magnesium and phosphorus. Lancet 352 (1998) 391-396
19. Bokemeyer C., Berger C.C., Kuczyk M.A., et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14 (1996) 2923-2932
20. Martin M., Diaz-Rubio E., Casado A., et al. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Am J Clin Oncol 15 (1992) 348-351
21. Al-Ghamdi S.M.G., Cameron E.C., and Sutton R.A.L. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 24 (1994) 737-752
22. Macaulay V.M., Begent R.H.J., Phillips M.E., et al. Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol 9 (1982) 179-181
23. Patterson W.P., and Reams G.P. Renal toxicities of chemotherapy. Semin Oncol 19 (1992) 521-528
24. Goren M.P., Wright R.K., Horowitz M.E., et al. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 18 (1986) 69-73
25. Sartori S., Nielsen I., Tassinari D., et al. Changes in intracellular magnesium concentrations during cisplatin chemotherapy. Oncology 50 (1993) 230-234
26. Evans T.R.J., Harper C.L., Beveridge I.G., et al. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 31A (1995) 174-178
27. Winkler C.F., Mahr M.M., and DeBandi H. Cisplatin and renal magnesium wasting. Ann Intern Med 91 (1979) 502-503
28. Willox J.C., McAllister E.J., Sangster G., et al. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54 (1986) 19-23
29. Mavichak V., Coppin C.M.L., Wong N.L.M., et al. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci 75 (1988) 203-207
30. Bianchetti M.G., Kanaka C., Ridolfi-Luthy A., et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol 4 (1990) 219-222
31. Bianchetti M.G., Kanaka C., Ridolfi-Luthy A., et al. Persisting renotubular sequelae after cisplatin in children and adolescents. Am J Nephrol 11 (1991) 127-130
32. Ariceta G., Rodriguez-Soriano J., Vallo A., et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28 (1997) 35-40
33. Ashraf M., Scotchel P.L., Krall J.M., et al. Cis-Platinum-induced hypomagnesaemia and peripheral neuropathy. Gynecol Oncol 16 (1983) 309-318
34. Flombaum C.D. Hypomagnesemia associated with cisplatin combination chemotherapy. Arch Intern Med 144 (1984) 2336-2337
35. Hill J.B., and Russo A. Cisplatin-induced hypomagnesemic hypocalcaemia. Arch Intern Med 141 (1981) 1100
36. Stuart-Harris R., Ponder B.A.J., and Wrigley P.F.M. Tetany associated with cis-platin. Lancet 2 8207 (1980) 1303
37. Netten P.M., de Mulder P.H.M., Theeuwes A.G., et al. Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesaemia. Ann Oncol 1 (1990) 369-372
38. Rosenthal C.J., Khulpateea N., Boyce J., et al. Effective chemotherapy for advanced carcinoma of the cervix with bleomycin, cisplatin, vincristine and methotrexate. Cancer 52 (1983) 2025-2030
39. Kibirige M.S., Morris-Jones P.H., and Addison G.M. Prevention of cisplatin-induced hypomagnesemia. Pediatr Hematol Oncol 5 (1988) 1-6
40. Abbasciano V., Mazzotta D., Vecchiatti G., et al. Changes in serum, erythrocyte, and urinary magnesium after a single dose of cisplatin combination chemotherapy. Magnes Res 4 (1991) 123-125
41. Skinner R., Pearson A.D.J., English M.W., et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77 (1998) 1677-1682
42. Markman M., Rothman R., Reichman B., et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol 117 (1991) 89-90
43. Fossa S.D., Lehne G., Heimdal K., et al. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 52 (1995) 300-305
44. Nogueira P.C.K., Hadj-Aissa A., Schell M., et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 12 (1998) 572-575
45. Lofts F.J., Evans T.R.J., Wastnage R., et al. Magnesium supplements with cisplatin chemotherapy. Eur J Cancer 32A (1996) 556-557